When a drug is commercialized, it is always monitored by a pharmacovigilance system to evaluate its risks. This system involves healthcare professionals, CRPVs, and the ANSM. These monitoring activities include collecting a significant amount of data that have to be analyzed and sorted to take corrective measures if needed.
The Medication Shield technology was developed to make the management of ADR reports easier for pharmacovigilant experts.
This was made possible thanks to the collaboration of the CRPVs pharmaceutical expertise, the ANSM, and Synapse Medicines' technology, which is beneficial to the populations' safety.
Dr. Louis Letinier - Medical Director and Co-Founder Synapse Medicine
Létinier, L. et al. Artificial intelligence for unstructured healthcare data: application to coding of patient reporting of adverse drug reactions.Clin. Pharmacol. Ther. 110, 392–400 (2021).